Download Free Liver Cancer Multidisciplinary Approach Book in PDF and EPUB Free Download. You can read online Liver Cancer Multidisciplinary Approach and write the review.

Hepatocellular carcinoma (HCC) represents one of the most significant health issues globally, given its high prevalence and challenging nature of liver physiology and hepatic surgery. This means that the most appropriate management of HCC should include a multidisciplinary approach, combining expertise from various specialties. This book showcases the steps involved in the development, diagnosis, staging, and management of HCC and provides us with the views and thoughts of true experts in the field. As such, it is a useful companion for any physician or surgeon, whether training or practicing, who is interested in caring for these patients.
Image-Guided Cancer Therapy: A Multidisciplinary Approach provides clinicians with in-depth coverage of the growing, dynamic field of interventional oncology. Combining the knowledge of expert editors and authors into one powerhouse reference, this book looks at tumor ablation, HIFU, embolic therapies, emerging technologies, and radiation therapy throughout the body (liver, bone, breast, gynecologic and prostate cancers, to name just a few) , and includes discussion of different imaging modalities. In the words of Peter Mueller, MD, author of the book’s Foreword: “... The senior authors are all world renowned experts in interventional oncology, which is another example of the high quality authorship and experience that is brought to this book. The later chapters discuss therapies that are simply not covered in any other source. Everyone who is doing or wants to do ablation therapies and interventional oncology will face a time when they will be asked to use their expertise in less used and less investigated areas. There is nowhere else where the reader can get information on the prostate, breast, and gynecologic areas, and especially pediatrics....This book is an outstanding contribution to the literature and will become a ‘must read’ for all physicians who are interested in Interventional Oncology.”
This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.
Colorectal cancer is the third most commonly diagnosed condition in oncology, affecting around 1.23 million individuals per year, according to recent statistics. Of these patients, about 50% will develop liver metastases and approximately 20% will present a stage IV disease at diagnosis. These statistics make colorectal liver metastases (CLM) an issue of major importance in current oncology. The area of CLM is subject to great and continuous advances, as its pathophysiologic mechanisms are better understood and more therapeutic and surgical options are developed. Consequently, all professionals involved with the diagnosis, treatment and follow up of CLM should be kept up to date with the latest advances on the field, to provide high standard medical care to their patients. This book is designed to present the state-of-the-art in CLM management and, in doing so, to review the current evidence on CLM, discussing all important topics in the field. Coverage is broad and comprehensive, encompassing introductory topics (history, definitions, epidemiology, etc.), basic science subjects (molecular biology, genetics, dissemination process, etc.) and practical clinical topics (tumor behavior, diagnosis, drug therapy, radiation therapy, surgery, ablation, multidisciplinary teams, etc.). Although comprehensive on the coverage and selection of topics, each chapter is concise and objective, dissecting topics in a practical and direct format. Evidences and recommendations are included. Chapters display a brief introduction of the common knowledge, go straight to the detailed revision of the most recent years of the literature, and end with practical closing observations. This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases.
The second edition of this book is intended as a definitive text on biliary tract and gallbladder cancers. Specifically, it will serve as a single-source reference on the current knowledge base for the multidisciplinary management of such cancers and thus covers epidemiological, surgical, radiotherapy, and chemotherapy approaches. A key feature is the demonstration of the impact of cutting-edge technical knowledge on treatment; for example, interventional radiology techniques, novel surgical approaches, and image-guided radiation therapy are all extensively discussed. Diagnosis is also considered in detail, with coverage of novel serum biomarkers, pathologic staging, molecular profiling, and the full range of current and emerging imaging strategies. This book will be an invaluable source of information on new techniques for experienced practitioners, yet is sufficiently concise to offer an introduction to the field for students and community practitioners.
This book provides a comprehensive, state-of-the-art overview of cholangiocarcinoma (CCA). The text is structured to effectively present a broad yet concise overview of bile duct cancer, its relevant definitions, classification schemata, clinical management tenets, translational (including molecular and cellular) facets, and future directions. The book features numerous high-yield illustrations and is authored by an eclectic range of renowned experts in various areas of CCA, reflecting the multidisciplinary nature of the field. Filling a critical gap in the field, Diagnosis and Management of Cholangiocarcinoma: A Multidisciplinary Approach is a valuable resource for clinicians and practitioners who treat patients with bile duct cancer.
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
This book is intended as a comprehensive resource for clinicians and researchers seeking in-depth information on geriatric oncology. The coverage encompasses epidemiology, the biology and (patho)physiology of aging and cancer, geriatric assessment and management, hematologic malignancies, solid tumors, issues in patient care, and research methods. Since cancer is a disease of aging and people are living longer, most cancer patients are now aged 70 and older. Yet the more we age, the more diverse we become in terms of our health, biologic fitness, and cancer behavior. Typically, however, general oncology clinical trials address only a selected healthier and younger population of patients. Geriatric oncology is the area of oncology that addresses these issues but while a wealth of knowledge has been accumulated, information is often difficult to retrieve or insufficiently detailed. The SpringerReference program, in which this book is published, offers an ideal format for overcoming these limitations since it combines thorough coverage with access to living editions constantly updated chapter by chapter via a dynamic peer-review process, ensuring that information remains current and pertinent.
The second edition, which appears seven years after the first, is a more comprehensive text and addresses the many recent advances in basic and clinical science applicable to autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune aspects of viral-, drug- and alcohol-induced liver disease and hepatocellular cancer. Pathogenesis, diagnosis and treatment are discussed in depth in light of current understanding of the molecular mechanisms of autoimmunity as it applies to liver disease.